Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZSOTCMKTS:ASPCFNASDAQ:JBIONASDAQ:KTTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.57-1.2%$3.30$3.96▼$12.00$6.40M1.557,305 shs5,715 shsASPCFAcerus Pharmaceuticals$0.22$0.22$0.22▼$8.16$1.70M0.691,500 shsN/AJBIOAerovate Therapeutics$6.76-2.6%$0.00$6.57▼$884.97$5.69M0.9393,846 shs240,117 shsKTTAPasithea Therapeutics$0.79-5.2%$1.15$0.77▼$7.50$5.85M0.332.07 million shs290,893 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris+0.42%-2.82%+3.29%+9.88%-45.80%ASPCFAcerus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%JBIOAerovate Therapeutics-2.59%+675,999,900.00%+675,999,900.00%+675,999,900.00%+675,999,900.00%KTTAPasithea Therapeutics-5.21%-11.27%-17.71%-29.19%-86.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/AASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AJBIOAerovate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKTTAPasithea Therapeutics1.5776 of 5 stars0.05.00.00.02.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/AASPCFAcerus Pharmaceuticals 0.00N/AN/AN/AJBIOAerovate Therapeutics 0.00N/AN/AN/AKTTAPasithea Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.70N/AN/A$14.99 per share0.24ASPCFAcerus Pharmaceuticals$2.12M0.80N/AN/A($3.38) per share-0.07JBIOAerovate TherapeuticsN/AN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/A$22.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)ASPCFAcerus Pharmaceuticals-$33.82M-$3.57N/A∞N/A-924.33%N/A-74.62%N/AJBIOAerovate TherapeuticsN/A-$59.65N/A∞N/AN/AN/AN/AN/AKTTAPasithea Therapeutics-$15.96M-$10.60N/A∞N/AN/A-81.57%-74.31%8/11/2025 (Estimated)Latest ASPCF, KTTA, JBIO, and AEZS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025KTTAPasithea TherapeuticsN/A-$1.61N/A-$1.61N/AN/A3/24/2025Q4 2024KTTAPasithea TherapeuticsN/A-$2.41N/A-$2.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/AASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/AJBIOAerovate TherapeuticsN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93ASPCFAcerus PharmaceuticalsN/A0.670.34JBIOAerovate TherapeuticsN/AN/AN/AKTTAPasithea TherapeuticsN/A14.8214.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%ASPCFAcerus PharmaceuticalsN/AJBIOAerovate TherapeuticsN/AKTTAPasithea Therapeutics23.92%Insider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%ASPCFAcerus PharmaceuticalsN/AJBIOAerovate Therapeutics24.90%KTTAPasithea Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataASPCFAcerus Pharmaceuticals147.71 millionN/ANot OptionableJBIOAerovate Therapeutics20841,000N/AN/AKTTAPasithea Therapeutics37.44 million1.06 millionNot OptionableASPCF, KTTA, JBIO, and AEZS HeadlinesRecent News About These CompaniesPasithea Therapeutics Appoints Dr. James Lee to Scientific Advisory Board to Advance PAS-004 Development for Inflammatory DiseasesJune 12 at 7:49 PM | nasdaq.comPasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory BoardJune 11 at 7:02 AM | globenewswire.comPasithea Therapeutics Reports Promising Interim Results for PAS-004 in Phase 1 Trial for Refractory Solid Tumors at ASCO 2025June 5, 2025 | nasdaq.comPasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025June 2, 2025 | globenewswire.comPasithea Therapeutics Reports Promising Preclinical Data for PAS-004 as a Novel MEK Inhibitor for Inflammatory DiseasesMay 21, 2025 | nasdaq.comPasithea Announces Strong Preclinical Results For PAS-004 In Inflammatory Disease ModelMay 21, 2025 | nasdaq.comPasithea Therapeutics Stock Draws Retail Buzz As Early Data Shows Potential In Treating Inflammatory DiseasesMay 21, 2025 | msn.comPasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market DiseasesMay 20, 2025 | globenewswire.comPasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial SiteMay 14, 2025 | globenewswire.comPasithea Therapeutics Closes $5 Million Public Offering to Advance Development of PAS-004 for Neurofibromatosis and Cancer IndicationsMay 9, 2025 | nasdaq.comPasithea Therapeutics Announces Closing of $5 Million Public OfferingMay 7, 2025 | finance.yahoo.comPasithea Therapeutics Raises $6.3 Million in Stock OfferingMay 7, 2025 | tipranks.comPasithea Therapeutics Announces Closing of $5 Million Public OfferingMay 7, 2025 | globenewswire.comPasithea Therapeutics Announces Pricing of $5 Million Public OfferingMay 6, 2025 | finance.yahoo.comPasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s ElatedMay 6, 2025 | msn.comPasithea Therapeutics Announces Pricing of $5 Million Public OfferingMay 6, 2025 | globenewswire.comPasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial ResultsMay 6, 2025 | benzinga.comPasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004May 6, 2025 | globenewswire.comPasithea Therapeutics Advances Clinical Trial of PAS-004 for Neurofibromatosis and MAPK Pathway Driven CancersApril 29, 2025 | quiverquant.comPasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer PatientsApril 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASPCF, KTTA, JBIO, and AEZS Company DescriptionsAeterna Zentaris NASDAQ:AEZS$3.57 -0.05 (-1.24%) As of 06/13/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Acerus Pharmaceuticals OTCMKTS:ASPCF$0.22 0.00 (0.00%) As of 07/21/2023Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.Aerovate Therapeutics NASDAQ:JBIO$6.76 -0.18 (-2.59%) As of 06/13/2025 04:00 PM EasternAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Pasithea Therapeutics NASDAQ:KTTA$0.79 -0.04 (-5.21%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.80 +0.01 (+1.53%) As of 06/13/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
